Huang Li, Zhong Xiaoting, Li An, Tu Fuping, He Miao, Xu Xueming, Liu Xiaohui, Zeng Xiaoli, Chi Jun, Tian Tian, Wang Chunli, Wang Xiangcai, Ye Jianming
Department of oncology, First Affiliated Hospital, Gannan Medical University, Ganzhou, China.
Jiangxi Clinical Medical Research Center for Cancer, Ganzhou, China.
Cancer Cell Int. 2024 Jun 4;24(1):197. doi: 10.1186/s12935-024-03377-3.
Syntaxin6 (STX6) is a SNARE (Soluble N-ethylmaleimide-sensitive factor attachment protein receptors) protein complex located in the trans-Golgi network and endosomes, which is closely associated with a variety of intracellular membrane transport events. STX6 has been shown to be overexpressed in a variety of human malignant tumors such as esophageal, colorectal, and renal cell carcinomas, and participates in tumorigenesis and development.
Based on clinical public database and clinical liver samples analysis, the expression of STX6 in hepatocellular carcinoma (HCC) tissues was investigated. The effects of STX6 on proliferation, migration and invasion of HCC cell in vitro and in vivo were evaluated through gain- and loss-of-function studies. We further performed RNA-seq analysis and protein interactome analysis, to further decifer the detailed mechanisms of STX6 in the regulation of the JAK-STAT pathway in HCC.
STX6 expression was upregulated in HCC tissues and its expression was highly correlated with the high histological grade of the tumor. STX6 promoted HCC cell proliferation, migration and invasion both in vitro and in vivo. Mechanistically, STX6 mediated tumor progression depending on promoting the activation of JAK-STAT signaling pathway. Receptor for activated protein kinase C (RACK1) as an essential adaptor protein mediating STX6 regulation of JAK-STAT pathway. Specifically, STX6 interacted with RACK1 and then recruited signal transducer and activator of transcription 3 (STAT3) to form a protein-binding complex and activates STAT3 transcriptional activity.
This study provided a novel concept that STX6 exerted oncogenic effects by activating the STAT3 signaling pathway, and STX6 might be a promising therapeutic target for HCC.
Syntaxin6(STX6)是一种可溶性N - 乙基马来酰亚胺敏感因子附着蛋白受体(SNARE)蛋白复合物,位于反式高尔基体网络和内体中,与多种细胞内膜运输事件密切相关。已表明STX6在多种人类恶性肿瘤如食管癌、结直肠癌和肾细胞癌中过表达,并参与肿瘤发生和发展。
基于临床公共数据库和临床肝脏样本分析,研究STX6在肝细胞癌(HCC)组织中的表达。通过功能获得和功能缺失研究评估STX6对HCC细胞体外和体内增殖、迁移和侵袭的影响。我们进一步进行了RNA测序分析和蛋白质相互作用组分析,以进一步阐明STX6在HCC中调节JAK - STAT通路的详细机制。
STX6在HCC组织中表达上调,其表达与肿瘤的高组织学分级高度相关。STX6在体外和体内均促进HCC细胞增殖、迁移和侵袭。机制上,STX6通过促进JAK - STAT信号通路的激活介导肿瘤进展。活化蛋白激酶C受体(RACK1)作为一种重要的衔接蛋白介导STX6对JAK - STAT通路的调节。具体而言,STX6与RACK1相互作用,然后招募信号转导和转录激活因子3(STAT3)形成蛋白质结合复合物并激活STAT3转录活性。
本研究提出了一个新的概念,即STX6通过激活STAT3信号通路发挥致癌作用,并且STX6可能是HCC的一个有前景的治疗靶点。